Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.70 |
| ▸ | DRD3 | P35462 | 6/20 | 0.70 |
| ▸ | DRD4 | P21917 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8523324 | 1.00 | DRD2 (0.70) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL9773160 | 1.00 | DRD2 (0.70) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL9773116 | 0.86 | DRD2 (0.56) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL9773119 | 0.86 | DRD2 (0.56) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL3849923 | 0.84 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL8470779 | 0.83 | DRD2 (0.65) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL8470799 | 0.83 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL8470803 | 0.83 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL8472405 | 0.82 | DRD2 (0.98) | DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL8472401 | 0.82 | DRD2 (0.98) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | claimed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | claimed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | claimed |
| EP-1870405-A1 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2007-12-26 | — | — | EP | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
| EP-1870405-A1 | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2007-12-26 | — | — | EP | disclosed |
| US-5977110-A | Substituted cyclohexylamines as central nervous systems agents | WARNER-LAMBERT COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1997011070-A1 | SUBSTITUTED CYCLOHEXYLAMINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| US-5047406-A | Substituted cyclohexanols as central nervous system agents | WARNER-LAMBERT CO. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0431580-A2 | Substituted cyclohexanols as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD2 4/4885DRD3 1/4885DRD4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.